Recent Updates
Recently added Catalysts
FBRX Positive Sentiment

FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period

Thursday, July 9, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Forte Biosciences, Inc. reported positive results from its phase 1b study of FB102 for vitiligo. The treatment achieved a 29.6% mean improvement in the FVASI score at week 24, with significant results noted as early as week 9. The study was conducted in a double-blind, placebo-controlled manner.
Price reaction · baseline $20.58 (2026-07-08 close) · hit pre-market · clean, no other FBRX news in the window
day 0 close
+78.3%
day 1 · peak
+113.4%
day 3
+109.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • FB102 showed a statistically significant improvement in vitiligo.
  • The treatment demonstrated early response by week 9.
  • The study was double-blind and placebo-controlled, enhancing credibility.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+391%
120-day peak, hindsight
Typical move
1.4%
average across 3 past catalysts
Cash runway
~26 mo
Minimal dilution risk
Lead asset
FB-401
Phase 2 · Atopic Dermatitis

Full Press Release Details

DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive results from the FB102 double-blind placebo-controlled phase 1b study in vitiligo: FB102 achieved 29.6% mean FVASI improvement from baseline at week 24 (p-value = 0.020) Response to FB102 was observed early, with statistically significant improvements observed by the day 64 visit (p=0.023)

Frequently Asked Questions

What is FB102?

FB102 is a treatment developed by Forte Biosciences for vitiligo.

What were the results of the FB102 study?

The study showed a 29.6% mean improvement in vitiligo at week 24.

What type of study was conducted for FB102?

A double-blind placebo-controlled phase 1b study was conducted.

When were improvements observed in the study?

Statistically significant improvements were observed by week 9.

ShareAdd on Google
Tags: FBRX Viatris Investor Conferences Healthcare Forte Biosciences FB102 vitiligo clinical trial
Last updated: Jul 9, 2026

Biotech snapshot

Cash runway
$198M liquidity · $8M/mo burn
~26 mo
Minimal dilution risk
Lead asset
FB-401Phase 2
Atopic Dermatitis →

Catalyst track record

+391%
best trade around FBRX's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for FBRX.

See every catalyst's timing & PoA →